|
Urology News and Education Resource
 |
Tuesday, 23 June 2026 |
|
|
|
 |
|
The 2018 Genitourinary Cancers Symposium “Translating Evidence to Multidisciplinary Care” will feature an array of sessions covering prostate, renal, urothelial, testicular, and adrenal cancers. World-renowned faculty will present on the most clinically relevant topics across these disease sites and offer insight into the future of cancer care for GU malignancies.
This year, the program will include case-based discussions and debates in each disease site to highlight the clinical application of the latest research in the field. Topics for these presentations include “Magnetic Resonance and Magnetic Resonance-Directed Biopsy in Localized Prostate Cancer: Where is the Field Moving?,” “Multimodality Approach to Locally Advanced Bladder Cancer,” “Management of Residual Masses in Germ Cell Tumors,” and “Comprehensive Characterization and Management of the Incidental Renal Mass.”
Subspecialties represented on these and other panels in the program include medical oncology, radiation oncology, surgery, urology, and pathology. UroToday/GU OncToday is pleased to deliver real-time coverage from San Francisco offering extensive coverage on the full agenda and several select abstracts beginning Thursday, February 8.
|
|
|
Case-Based Debate: Magnetic Resonance and Magnetic Resonance-Directed Biopsy: Where Is the Field Moving?
Christopher J. Kane, Ivan Pedrosa, Mark Emberton
Newly Diagnosed High-Risk Disease Treatment: Summarizing Neoadjuvant Trials
Mary-Ellen Taplin
Adjuvant Radiotherapy and Chemotherapy in Node-Positive Disease
Alberto Briganti |
|
|
Case-Based Debate: Radiotherapy After Prostatectomy: Adjuvant Versus Early Salvage Paul L. Nguyen, Christopher L. Amling, William U. Shipley
Ten year final results of the TROG 03.04 (RADAR) randomised phase 3 trial evaluating duration of androgen suppression ± zoledronate for locally advanced prostate cancer.
David John Joseph
Emerging Diagnostics and Therapies in Advanced Prostate Cancer
Himisha Beltran, William L. Dahut |
|
|
|
Emerging Immunotherapy Strategies for Castrate Resistant Prostate Cancer
Padmanee Sharma
Management of Oligometastatic Prostate Cancer From Imaging to Therapy
Felix Y. Feng
Incorporating Genomics Into the Management of Systemic Therapy: Advances and Practicality
Kim N. Chi
Molecular Therapies in Bone Metastases
Joe M. O'Sullivan
Abstract 160: Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.
Andrew J. Armstrong
Ten year final results of the TROG 03.04 (RADAR) randomised phase 3 trial evaluating duration of androgen suppression ± zoledronate for locally advanced prostate cancer.
David John Joseph
PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).
Maha Hussain
Abstract 161: SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
Eric Jay Small
|
|
|
|
|
Germline and Somatic Mutational Landscape in Prostate Cancer: State of Knowledge and
Implications for Practice
Robert G. Bristow, Elisabeth I. Heath, Mack Roach III, Adam Dicker
Case-Based Debate: Abiraterone Versus Docetaxel
Nicholas J. Van As, Karim Fizazi, Gustave Roussy, Christopher Sweeney
Abstract 2: Transcriptomic heterogeneity of androgen receptor activity in primary prostate cancer: Identification and characterization of a low AR-active subclass.
Daniel Eidelberg Spratt
Rapid-Fire Abstract Session: Prostate Cancer
Paul L. Nguyen
Abstract 4: Daily versus weekly prostate cancer image-guided radiotherapy: A phase 3, multicenter, randomized trial.
Renaud de Crevoisier
Abstract 5: Hypoxia related mRNA biomarker to predict biochemical failure and metastasis for
prostate cancer.
Ananya Choudhury
Abstract 164: Comparative assessment of abiraterone or enzalutamide activity in the
PROREPAIR-B study.
Rebeca Lozano
Abstract 165: The FALCON trial: Impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer.
Eugene Jueren Teoh
|
|
|
|
|
|
|
|
